Vivos Inc (RDGL)

[WALLnut]

You raise valid concerns about the expired original patents, but the conclusion that RDGL’s opportunity is dead doesn't hold up under scrutiny.

1. Improved Formulations = New IP
While the original patents expired in 2022, RDGL has filed for protection on key enhancements—like gel viscosity, injectability, and tumor-targeting precision. These improvements matter clinically and can still be patent-protected, offering competitive advantage.


2. Mayo Clinic’s Involvement Speaks Volumes
Mayo Clinic doesn’t just “take money to run trials.” Their reputation and standards are too high for that. Their involvement signals that RDGL’s version offers clinical promise beyond what's available in the public domain.


3. Generics Don’t End Innovation
Many biotechs thrive even after original patents expire—by offering superior delivery systems, better safety profiles, or faster regulatory pathways. RDGL still has a first-mover advantage in delivering a precise Y90 injectable gel for soft tissue tumors.


4. Cost vs. Clinical Value
Hospitals and clinicians don’t just want “cheap.” They want effective, targeted therapies. If RDGL’s gel delivers superior outcomes with fewer side effects, it can command market share regardless of generic alternatives.


5. The Window Isn’t Closed
Delays are frustrating, but the need for better radiotherapeutic options remains. If RDGL secures IDE approval and enters trials, it can still carve out a valuable clinical and commercial role—based on data, not just IP.

$RDGL